MK-677 vs Ibutamoren
Head-to-head comparison of MK-677 (Ibutamoren Mesylate (MK-677)) and Ibutamoren (Ibutamoren mesylate (MK-677)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | MK-677 | Ibutamoren |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Ibutamoren Mesylate (MK-677) | Ibutamoren mesylate (MK-677) |
| Molecular Weight | 528.662 g/mol | N/A |
| Half-Life | ~24 hours | about 24 hours |
| Amino Acids | Non-peptide compound | N/A |
| Typical Dose | — | 10-25 mg/day |
| Route | — | Oral |
| Purity | >99% | ≥98% |
| Studies Count | 120 | 180 |
| Research Status | Active Research | Clinical |
MK-677 Benefits
- ✓Oral GH secretagogue, 24-hour GH elevation, increases IGF-1, improves sleep quality, increases lean mass, does not suppress natural GH
Ibutamoren Benefits
- ✓raises GH/IGF-1
- ✓increases appetite
- ✓supports lean mass retention
- ✓oral non-peptide secretagogue
MK-677 Dosing
10-25 mg orally once daily before bedtime. 25 mg is the most studied dose. Can be used long-term without cycling.
Ibutamoren Dosing
10-25 mg orally once daily|take consistently at the same time each day|monitor fasting glucose and edema in longer studies
MK-677 Side Effects
- ⚠Increased appetite, mild water retention, drowsiness, transient numbness, mild increase in fasting blood glucose with long-term use.
Ibutamoren Side Effects
- ⚠increased appetite
- ⚠water retention/edema
- ⚠somnolence or lethargy
Research Overview
MK-677
A landmark 2-year study in elderly adults demonstrated significant increases in lean mass, GH pulsatility, and IGF-1 to youthful ranges. Selectively agonizes GHS-R1a without increasing cortisol or prolactin.
Ibutamoren
Clinical studies show oral ibutamoren reliably elevates GH and IGF-1 over 24 hours with once-daily dosing. Body composition and appetite effects vary by population, and development has been limited by metabolic side effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.